Mitralign To Highlight Trialign™ System at EuroPCR 2016

Company Sponsored Symposium on Thursday, May 19: Trialign Transcatheter Annuloplasty for the treatment of tricuspid regurgitation

TEWKSBURY, MA – May 13, 2016 — Mitralign, Inc., an innovative developer of direct transcatheter mitral and tricuspid valve repair solutions will present its Trialign™ System for transcatheter tricuspid repair at the EuroPCR conference, one of the world’s leading conferences on cardiology. EuroPCR takes place in Paris, France at the Palais des Congrès from May 17 – 20.

Mitralign will be highlighted at the EuroPCR Innovators Day on May 16th, with Dr. Azeem Latib, from St. Rafaelle Hospital presenting the Trialign System for the treatment of tricuspid regurgitation. In addition, the company will sponsor a symposium on Thursday, May 19th chaired by Dr. Neil Moat, of the Royal Brompton Hospital, London, UK. The symposium will be held from 13:35 – 14:35 in room 241. Mitralign personnel will be available in the Palais de Congrès at booth P13 located on the second floor.

Mitralign is the only company to provide a direct transcatheter annuloplasty system, designed to treat both functional mitral regurgitation (FMR) and functional tricuspid regurgitation (FTR). The first application of this innovation, the Mitralign Percutaneous Annuloplasty System (MPAS) for FMR, earned CE Mark earlier this year. Trialign for FTR is being investigated in an early feasibility study in the US and is not approved for sale or distribution.

About Functional Tricuspid Regurgitation (FTR)
Tricuspid regurgitation occurs when the tricuspid valve fails to open and close properly, causing blood to flow backwards into the right atrium. If left untreated, TR can lead to heart enlargement and heart failure. In the US alone, there are at least 1.6 million patients suffering from moderate/severe TR¹. It is estimated that at least 50% of patients with mitral regurgitation have moderate to severe tricuspid regurgitation². TR is currently undertreated by surgery. According to one study, surgeons in the US treat only 5,500 patients per year, most of them in conjunction with left heart surgeries. When treating the valves, surgeons choose repair 90% of the time versus replacement (10%)³.
About Functional Mitral Regurgitation (FMR)
The mitral valve controls blood flow from the left atrium to the left ventricle of the heart, allowing blood to flow in one direction through the heart and into the body. Functional Mitral Regurgitation (FMR) is the most common valve disease and occurs when the left ventricle of the heart is enlarged and stretches the valve open. Subsequent to this remodeling, the valve leaflets are not able to come together and close properly, allowing blood to flow, or regurgitate, backwards into the atrium. Consequences can include heart failure or serious rhythm problems called arrhythmias. An estimated four million people in Europe and four million people in the United States have significant mitral valve insufficiency, also known as mitral regurgitation, with an annual incidence of 250,000. If left untreated, mitral regurgitation overloads the heart and can lead to or accelerate heart failure.

About Mitralign Inc.
Mitralign Inc. is the valve repair company with the only transcatheter direct annuloplasty system designed to treat both functional mitral regurgitation and tricuspid regurgitation. The company, a leader in transcatheter repair for tricuspid regurgitation is a venture-backed, medical innovation company located near Boston, Massachusetts, USA. For more information, visit www.mitralign.com.

2. Rogers JH. Circulation 2009;119: 2718-25

# # #

Company Contact:
David Schleifer
Vice President, Marketing
Mitralign Inc.
+617.869.6166
dschleifer@mitralign.com